fda semaglutide compounding warning november 2025 September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns – Partnership for Safe Medicines FDA and Novo Nordisk Warned

Underlying Health Conditions: Certain health issues, such as kidney disease, liver impairment, or a history of specific cancers, might contraindicate the use of certain medications or supplements

It is essential to determine whether changes are related to the medication, the process of weight loss, an underlying condition, or another factor

individuals with pre-existing retinopathy should be aware of this risk [28] [29] Pregnancy and breastfeeding incretin-based therapies should be avoided during pregnancy and breastfeeding unless within a supervised clinical trial, as safety data in these populations are absent Delayed gastric emptying a class effect of GLP-1 receptor agonists can reduce the absorption rate of concomitant oral medicines

The test identifies genetic variants in your GLP1R (rs6923761), GIPR, FTO, and MC4R pathways that influence your response to GLP-1 and GIP-based therapies